RapidAI

RapidAI is a company that offers AI-powered clinical decision support software specifically designed for stroke, aneurysm, and pulmonary embolism care. The company provides a comprehensive suite of products for stroke care, including Rapid NCCT, Rapid ICH, Rapid Hyperdensity, Rapid SDH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid MRI, and Rapid Workflow for Stroke. RapidAI’s platform is utilized in over 2,200 hospitals globally and has impacted 90 million lives through its technology. The company has participated in more than 25 clinical trials worldwide and has received multiple FDA clearances for its AI modules, such as Rapid PE, Rapid RV/LV, Rapid Hyperdensity, and Rapid LVO. Clinicians trust and validate RapidAI’s technology to enhance patient care and outcomes. RapidAI also offers RapidAI Insights, a suite of reports and analytics on Rapid scan, treatment, and outcomes data. The company provides training and continuing education through Rapid U, which includes on-demand learning, instructor-led training, and CE credits. With a global distribution network and partnerships with technology leaders, RapidAI brings its solutions to more hospital environments. The company has secured significant funding, including a $75 million growth investment led by Vista Credit Partners. RapidAI’s products have been extensively studied and validated in clinical trials, leading to improved clinical outcomes and new guidelines for stroke care. The platform is designed for speed, scalability, and security, with flexibility and customization to meet each hospital’s specific needs. RapidAI has been recognized with multiple awards, including the MedTech Breakthrough Award for Best New Imaging Solution. Additionally, the company offers RapidAI EMR Integration to enable secure data flow between the hospital EMR system and the Rapid Workflow solution.